Transgene (TNG)

Business description

Transgene is a French company developing immunotherapy agents for cancer and infectious diseases. Oncolytic virus Pexa-Vec (Phase III for HCC) and cancer vaccine TG4010 (Phase II for NSCLC) are the lead clinical candidates.

Potential confirmed but checkpoint data needed

Update | Pharmaceutical & healthcare | 03/06/2015

The therapeutic potential of Transgene’s TG4010 in non-squamous non-small cell lung cancer (NSCLC) was supported by the more mature overall survival (OS) Phase IIb data. However, we expect that additional data from combination studies with checkpoint inhibitors will be required for TG4010 to be out-licensed; these trials should start in H215. Transgene is also planning to initiate a Phase I study with TG1050 for chronic HBV infection. We maintain our valuation at €464m.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€193.7m
Last close€3.120
High / Low (52 weeks)€3.6 / €2.5
Stock market listingEU
Forecast net debt (€m)29.4
Forecast gearing ratio (%)164
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual3.116.014.3
Relative *8.216.64.7

* % Relative to local index

Company news

Transgene

Thu, 08 Jun 2017 16:02:29 GMT

Transgene

Thu, 12 Nov 2015 07:00:34 GMT

Transgene

Tue, 20 Feb 2018 00:11:13 GMT

Transgene

Wed, 03 Feb 2016 16:52:30 GMT

Transgene

Tue, 13 Feb 2018 18:56:15 GMT